NACDS NEW CHAIRMAN IS HARCO DRUG's JAMES HARRISON; PERRY's ROBINSON TO TREASURER
Harco Drug Chairman James Harrison Jr. will lead the Natl. Assn. of Chain Drug Stores (NACDS) in 1985, the assn. announced April 28. At the NACDS annual meeting in Palm Beach, Fla., Harrison was elected assn. chairman. He succeeds Longs Drug Chairman and Chief Exec Officer Robert Long. A board member since 1978, Harrison has served on the NACDS exec cmte. since 1980. The assn's. new vice chairman is Rite Aid's Alex Grass. As vice chairman, Grass is in line to assume the chairman post in 1986. The Rite Aid chairman and president served as NACDS treasurer during 1984. Moving into the NACDS chain of leadership is Perry Drug Chairman and President Jack Robinson, elected to the treasurer's post. Robinson joined the assn's. board in 1983. Robinson also joins the NACDS Exec Cmte., along with Jack Eckerd Chairman and President Stewart Turley. The two replace Fay's Chairman Henry Panasci Jr. and Thrift Drug President James Amor, "who have been rotated off the Exec Cmte. in accordance with its membership policy," NACDS explained. Nine board members were re-elected for three-year terms expiring in 1988. The nine members are: Revco President Sidney Dworkin; Peoples Chairman and President Sheldon Fantle; Genovese Chairman and President Leonard Genovese; Rite Aid's Grass; May's Drug President Gerald Heller; LaVerdiere's Super Drug Stores President Reginald LaVerdiere; Perry's Robinson; Drug-Sav President M. W. Simpson; and Jack Eckerd's Turley.(ITEM 190)Picture 1, James Harrison Jr. NACDS Chairman; Picture 2, Alex Grass NACDS Vice Chairman; Picture 3, Jack Robinson NACDS Treasurer
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth